Treating GvHD: current challenges and newly approved drugs

Katie Gatwood

Graft versus host disease (GvHD) remains to be one of the leading causes of morbidity and mortality in patients who have undergone bone marrow transplant. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, briefly discusses the challenges with current treatment options for GvHD and gives an update on newly approved drugs that can be used to effectively treat patients. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

Share this video  
Similar topics
Related videos
2:19
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon
2:30
Matched unrelated donor (MUD) transplantations for ALL and AML
Arnon Nagler
1:19
Cytokine storms: CAR T-cell hyperinflammatory response distinct from cytokine release syndrome?
Nirali Shah
1:58
The importance of BOPA
Islam Elkonaissi
3:57
Why is supportive care important in myeloma?
Heinz Ludwig
General
Ibrutinib, Ruxolitinib
HOPA 2018
Interview
21st March 2018
More from Katie Gatwood
Ruxolitinib and ibrutinib: the future for GvHD treatment?
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals